-
Mashup Score: 1Next generation BRAF inhibitor cancer drug shows promise in early patient trial - ENA 2020 - 4 year(s) ago
Latest News Next generation BRAF inhibitor cancer drug shows promise in early patient trial A new drug designed to work on cancers with an altered BRAF gene has shown promise in an early patient trial presented at the 32th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, which is taking place online. The BRAF gene
Source: ENA 2020Categories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2Homepage - ENA 2020 - 4 year(s) ago
ENA 2020 is the drug development and translational research meeting, focusing on preclinical & phase I studies and the latest developments in targets and drugs.
Source: ENA 2020Categories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Homepage - ENA 2020 - 4 year(s) ago
ENA 2020 is the drug development and translational research meeting, focusing on preclinical & phase I studies and the latest developments in targets and drugs.
Source: ENA 2020Categories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Homepage - ENA 2020 - 4 year(s) ago
ENA 2020 is the drug development and translational research meeting, focusing on preclinical & phase I studies and the latest developments in targets and drugs.
Source: ENA 2020Categories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1Homepage - ENA 2020 - 4 year(s) ago
ENA 2020 is the drug development and translational research meeting, focusing on preclinical & phase I studies and the latest developments in targets and drugs.
Source: ENA 2020Categories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Homepage - ENA 2020 - 4 year(s) ago
ENA 2020 is the drug development and translational research meeting, focusing on preclinical & phase I studies and the latest developments in targets and drugs.
Source: ENA 2020Categories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 4Homepage - ENA 2020 - 4 year(s) ago
ENA 2020 is the drug development and translational research meeting, focusing on preclinical & phase I studies and the latest developments in targets and drugs.
Source: ENA 2020Categories: Hem/Oncs, Latest HeadlinesTweet-
I cannot wait for #ENASYMP20 sponsored by @EORTC @theNCI @AACR . Exceptional program by Drs. Gulley @gulleyj1 @nciccr_gmb, Sellers @broadinstitute and Calvo @TheSTARTCenter. I am humbled to give a Keynote with Sir Peter Ratcliffe @TheCrick https://t.co/nst4RKRUj4 #HIF #VEGF #RCC https://t.co/EdalRDc6pf
-
-
Mashup Score: 2Call for Abstracts - ENA 2020 - 4 year(s) ago
Abstracts submitted for presentation in the EORTC-NCI-AACR Symposium will be reviewed by an international panel of experts.
Source: ENA 2020Categories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Call for Abstracts - ENA 2020 - 4 year(s) ago
Call for Abstracts Abstracts submitted for presentation in the EORTC-NCI-AACR Symposium will be reviewed by an international panel of experts in the field of the subject and will be judged solely on the data submitted. The final decision on the presentation format of all selected abstracts lies at the sole discretion of
Source: ENA 2020Categories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Call for Abstracts - ENA 2020 - 4 year(s) ago
Call for Abstracts Abstracts submitted for presentation in the EORTC-NCI-AACR Symposium will be reviewed by an international panel of experts in the field of the subject and will be judged solely on the data submitted. The final decision on the presentation format of all selected abstracts lies at the sole discretion of
Source: ENA 2020Categories: Hem/Onc News and Journals, Latest HeadlinesTweet
#ENASymp Next generation BRAF inhibitor cancer drug shows promise in early patient trial https://t.co/Ph2GQbWjgS https://t.co/kx6KnOcaYL